The Sooran Noroozi Sarcoma Research Award: Honoring Resilience

We are delighted to share that the incredible story of Sooran Noroozi’s resilience and the launch of the Sooran Noroozi Sarcoma Research Award has been prominently featured on Global News. This award, established in memory of Sooran Noroozi, celebrates his legacy of courage and determination in the face of sarcoma. It is a tribute to the unwavering dedication of our medical professionals, including Dr. Ramy Saleh, Dr. Joseph Petrucelli, Dr. Anthony Bozzo and other experts, who tirelessly push the boundaries of science to improve patient outcomes.

Sooran’s journey, battling sarcoma while eagerly awaiting the birth of his daughter, is a poignant reminder of the strength and hope that permeates our research community. His story reflects the resilience and spirit of countless individuals affected by sarcoma, inspiring us to continue our mission of advancing sarcoma research and providing compassionate care.

We extend our heartfelt gratitude to Global News for spotlighting this meaningful initiative and highlighting the collaborative efforts that drive our ongoing work in sarcoma research. Together, we strive to make a difference and honor Sooran’s legacy every step of the way.

Polaris Phase III study now recruiting patients!

Join the New Polaris Clinical Trial – Phase III study now recruiting patients with Leiomyosarcoma! Discover cutting-edge treatments and contribute to advancing sarcoma research. Contact us for more information and eligibility criteria.

Visit the Clinical Trials table for more information.

Advancing Innovations with CQDM Funding

CQDM announces funding for three cancer research projects, supported by the Québec government grant. These projects aim to enhance cancer treatment efficacy and reduce side effects. They include Theratechnologies’ platform for colorectal cancer, Saydi Biotech’s MDM2 inhibitor for various cancers, and Roche Canada’s use of circulating tumor DNA for monitoring DLBCL patients. Dr. Ramy Saleh, along with other collaborators, plays a crucial role in Saydi Biotech’s project, emphasizing Québec’s leadership in innovative cancer research.

Join Our GIST Support Group

This group has been created by SaRC-Q to offer a space for sharing, support, and mutual assistance to all those living with GIST (Gastrointestinal Stromal Tumor) in Quebec and Canada. Our goal is to create a supportive and caring community where everyone feels supported and understood. Together, we can help each other overcome the challenges related to GIST and find resources to improve our quality of life. SaRC-Q will be sharing advancements in GIST treatments and insights about this sarcoma, as well as scientific and medical data.

TGCT Trials Now Recruiting Patients From Across Canada

Trials involving Tenosynovial Giant Cell Tumor (TGCT) in Canada now welcome participants from all regions across the country. If you would like to participate in these clinical trials, lodging and transportation are offered to facilitate the participation of eligible individuals. This assistance aims to ensure that geographical distance does not pose a barrier for patients interested in contributing to TGCT research. Prospective participants are encouraged to contact the trial coordinators or investigators to inquire about specific details regarding lodging and transportation arrangements for the particular trial they are interested in.

Sisters Confront Osteosarcoma: A Journey Guided by Dr. Saleh

Montreal, January 26, 2024 – Driven by an extraordinary spirit, the Harding sisters, Cassandra and Katelyn, have faced the same rare cancer—Osteosarcoma—within months of each other. This rare form of cancer, also battled by the iconic Terry Fox, has become a testament to the strength and courage inspired by SaRC-Q co-founder Dr. Ramy Saleh.

Katelyn, a 19-year-old athlete with a passion for rugby and ringette, initially attributed her pain and numbness to sports injuries. However, an X-ray revealed a harsh reality—she, too, was diagnosed with Osteosarcoma, following in the footsteps of her sister Cassandra, who had completed her own treatments six months prior.

Both sisters, tragically losing their mother to cancer, prompted Dr. Saleh and the medical team to investigate a potential genetic link. Tests revealed the presence of the P53 genetic variant in both sisters, predisposing them to a higher risk of developing multiple cancers.

Dr. Ahmed Aoude, a spine and orthopedic oncology surgeon at MUHC, described Katelyn’s surgery as “one of the biggest surgeries in modern medicine.” Despite the complexity and duration of the procedure, the sisters, who have shared their journey on social media, continue to inspire other young patients.

Cassandra is now in remission, while Katelyn, halfway through chemotherapy, undergoes rehabilitation to regain her ability to walk. The Harding family, supported by the Montreal’s MUHC medical staff, remains a beacon of hope and strength in the face of adversity.

To follow their inspiring journey guided by SaRC-Q co-founder Dr. Ramy Saleh, stay connected with us on social media and visit our website for updates on sarcoma research and patient stories.

Source: Pamela Pagano, CityNews

Insights into Radiation-Induced Sarcomas of the Breast

In a groundbreaking study, researchers led by Vanessa Di Lalla at McGill University have conducted a comprehensive review of Radiation-Induced Sarcomas (RISs) of the breast, offering valuable insights into a rare yet critical aspect of cancer treatment.

The findings, spanning a 20-year period, shed light on the incidence, risk factors, management, and outcomes of RISs, contributing significantly to the understanding of these complex malignancies.


Radiation-induced sarcomas (RISs) are a rare but serious consequence of radiotherapy, representing histologically proven sarcomas within or around previously irradiated sites. The study, conducted at McGill University Health Centre, focused on 19 patients meeting Cahan’s criteria for RISs between 2000 and 2020. The median age at RIS diagnosis was 72 years, with a median latency period of 112 months. All patients underwent surgery, and some received additional systemic therapy or reirradiation as salvage treatment.

At a median follow-up of 31 months, the study revealed that despite aggressive treatment, a significant proportion of patients experienced local recurrence, emphasizing the challenges in managing RISs. However, the overall survival outcomes at two years were encouraging, with a disease-specific survival of 88.9%.


The research underscores the need for specialized, multidisciplinary management of breast RISs, particularly in high-volume centers where expertise is readily available. While the study provides valuable insights, the researchers advocate for further investigations, emphasizing the rarity of RISs and the difficulty in drawing definitive conclusions on risk factors.

Read the Full Article

Unveiling Two New Clinical Trials

We are thrilled to announce the initiation of two groundbreaking clinical trials, marking significant strides in the field of sarcoma research. These trials, Abbisko Pimicotimib and PEAK, hold promise in advancing treatment options for patients facing GIST and TGCT challenges.

Abbisko Pimicotimib Trial: Embarking on a phase III journey, this trial is actively recruiting patients with inoperable TGCT (formerly known as PVNS). The study explores the efficacy of pimicotinib, a novel oral TKI, compared to a placebo, with permitted crossover. This represents a crucial step towards addressing the unique challenges posed by inoperable TGCT.

PEAK Trial: A phase III trial open for enrollment, PEAK focuses on patients with advanced GIST who are progressing or intolerant to imatinib. The trial investigates the combination of sunitinib and bezuclastinib versus sunitinib alone, offering a potential paradigm shift in the management of GIST cases.

We invite all eligible patients to consider participation, and healthcare professionals to reach out for patient enrollment. These trials signify our commitment to advancing sarcoma care, and we look forward to the impactful insights they will undoubtedly yield. Stay tuned for updates as we push the boundaries of sarcoma research.

Two New Promising Treatments

Exciting developments in sarcoma research have brought forth two promising treatments that hold immense potential for transforming the landscape of sarcoma care. SaRC-Q is thrilled to share the latest breakthroughs: Nirogacestat and CART Therapy.

1. Nirogacestat: Opening New Avenues in Sarcoma Treatment
Nirogacestat, a novel investigational drug, has shown promise in inhibiting the Notch signaling pathway, a key player in the growth of certain types of sarcoma. Early clinical trials indicate encouraging results, suggesting that Nirogacestat could be a game-changer in the pursuit of more effective and targeted sarcoma therapies. SaRC-Q is closely monitoring and participating in ongoing research to further evaluate the potential of Nirogacestat in the fight against sarcoma.

2. CART Therapy: Revolutionizing Immunotherapy for Sarcoma
Chimeric Antigen Receptor T-cell (CART) Therapy is an innovative form of immunotherapy that harnesses the power of the patient’s immune system to target and destroy sarcoma cells. This groundbreaking approach involves genetically modifying a patient’s T cells to express receptors that recognize and attack cancer cells. SaRC-Q is actively involved in exploring the efficacy and safety of CART Therapy in sarcoma patients through clinical trials. And, we are happy to share that the first patient was enrolled through McGill to Calgary’s CART Clinical trial. SaRC-Q remains dedicated to staying at the forefront of sarcoma research, relentlessly pursuing advancements that can make a meaningful difference in the lives of patients.

We will continue to provide updates on these promising treatments as we work towards a future where sarcoma is no longer a life-altering threat. Stay tuned for more updates, and let’s journey together towards a brighter future in sarcoma care!

First patient enrolled in new Clinical Trial

Thanks to the efforts and dedication of our co-founder Dr. Ramy Saleh, McGill enrolled the first patient into the Calgary’s Cart T cell trial for advanced alveolar soft-part sarcoma.

SaRC-Q Co-founder Dr. Ramy Saleh Leads Milestone in Sarcoma Research
In a significant milestone for sarcoma research, SaRC-Q co-founder Dr. Ramy Saleh has played a pivotal role in enrolling the first patient into the Calgary’s CART T-cell trial for advanced alveolar soft-part sarcoma (ASPS).

A Step Forward in Advanced Alveolar Soft-Part Sarcoma Treatment
Dr. Ramy Saleh’s dedication and tireless efforts have led to McGill’s enrollment in the cutting-edge CART T-cell trial, offering hope to those facing advanced alveolar soft-part sarcoma. CART T-cell therapy, a revolutionary immunotherapy approach, involves harnessing the patient’s immune system to target and combat cancer cells.

A Testament to SaRC-Q’s Commitment
This achievement underscores SaRC-Q’s commitment to pushing the boundaries of sarcoma research. Dr. Saleh’s leadership exemplifies the collaborative spirit and unwavering dedication of our team in advancing innovative treatments for rare and challenging forms of sarcoma.

A Brighter Future in Sarcoma Care
SaRC-Q congratulates Dr. Ramy Saleh and the entire team at McGill for this groundbreaking accomplishment. Enrolling the first patient into the Calgary’s CART T-cell trial is a significant step forward in our collective mission to transform the future of sarcoma care.

Stay tuned for further updates as we continue to strive for advancements that make a meaningful impact on the lives of sarcoma patients.